ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

NCT02517515 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

650

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus (HCV)

Interventions

DRUG: ombitasvir/paritaprevir/ritonavir and dasabuvir
DRUG: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir

Sponsor

AbbVie